CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
arimoclomoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244244
NCT00244244Phase 2Completed
CompareCT.gov

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

CytRx·interventional·Posted Oct 26, 2005·Updated Feb 9, 2012

In Brief

A Phase 2 clinical trial evaluating arimoclomol for Amyotrophic Lateral Sclerosis (ALS). Completed, across 10 sites.

Detailed Summary

The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis (ALS)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2005
Enrollment StartOct 1, 2005
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.7 years ago

Interventions

arimoclomoldrug